Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Therapeutic vaccines for prostate cancer.

Cha E, Fong L.

Curr Opin Mol Ther. 2010 Feb;12(1):77-85. Review.

PMID:
20140819
2.

Immunotherapeutics in development for prostate cancer.

Harzstark AL, Small EJ.

Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Epub 2009 Apr 2. Review.

3.

Immunotherapy for prostate cancer - recent progress in clinical trials.

Kipp RT, McNeel DG.

Clin Adv Hematol Oncol. 2007 Jun;5(6):465-74, 477-9. Review.

PMID:
17679921
4.

A year of successful cancer vaccines points to a path forward.

Morse MA, Whelan M.

Curr Opin Mol Ther. 2010 Feb;12(1):11-3. Review.

PMID:
20140811
5.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
6.

Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

McKarney I.

Issues Emerg Health Technol. 2007 Sep;(101):1-4.

PMID:
17763575
7.

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

Madan RA, Mohebtash M, Schlom J, Gulley JL.

Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi: 10.1517/14712590903321421.

PMID:
19857185
8.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
9.

Chemotherapy and immunotherapy combination in advanced prostate cancer.

Slovin S.

Clin Adv Hematol Oncol. 2012 Feb;10(2):90-100. Review.

PMID:
22402350
10.

Prostate cancer immunotherapy.

McNeel DG.

Curr Opin Urol. 2007 May;17(3):175-81. Review.

PMID:
17414515
11.

[Vaccine therapy of prostate cancer].

Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D.

Aktuelle Urol. 2005 Sep;36(5):407-16. Review. German.

PMID:
16163603
12.

Development of dendritic-cell based prostate cancer vaccine.

Tjoa BA, Murphy GP.

Immunol Lett. 2000 Sep 15;74(1):87-93. Review.

PMID:
10996633
13.

Cellular immunotherapies for prostate cancer.

McNeel DG.

Biomed Pharmacother. 2007 Jul;61(6):315-22. Epub 2007 Jan 26. Review.

PMID:
17306498
14.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
15.

New molecular targets in advanced prostate cancer.

Dawson NA.

Expert Rev Anticancer Ther. 2006 Jul;6(7):993-1002. Review.

PMID:
16831072
16.

Management of high risk metastatic prostate cancer: the case for novel therapies.

Brand TC, Tolcher AW.

J Urol. 2006 Dec;176(6 Pt 2):S76-80; discussion S81-2. Review.

PMID:
17084174
17.

Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.

Ragde H, Cavanagh WA, Tjoa BA.

J Urol. 2004 Dec;172(6 Pt 2):2532-8. Review.

PMID:
15538202
18.

Vaccine therapy for prostate cancer.

Sonpavde G, Spencer DM, Slawin KM.

Urol Oncol. 2007 Nov-Dec;25(6):451-9. Review.

PMID:
18047951
19.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
20.

Therapeutic options in advanced prostate cancer: present and future.

Sowery RD, So AI, Gleave ME.

Curr Urol Rep. 2007 Jan;8(1):53-9. Review.

PMID:
17239317

Supplemental Content

Support Center